Feature

AYA cancer: Bridging the divide


 

What’s next?

Among the recommendations of the authors of the AYA series in Blood is a call for assessing AYA-specific therapy in future clinical trials, as well as improved collaboration between adult and pediatric teams with involvement of multidisciplinary teams.

Many centers are already working on models for collaborative care, Dr. Salsman said, citing the Fort Worth AYA Oncology Coalition led by medical director Karen Albritton, MD, as an example of a program that has been successful in “getting stakeholders on the same page, helping them have a shared vision, and working to maximize improvements in outcomes.”

Patients are also taking the lead in demanding better care and attention to their psychosocial needs, Dr. Hanna said. In the case of the community-powered advocacy organization Critical Mass, they succeeded in getting lawmakers to introduce a bill in the U.S. House of Representatives that would allow college students to defer loan payments while undergoing cancer treatment.

Pages

Recommended Reading

When is the right time to stop treatment?
MDedge Hematology and Oncology
Salivary ductal adenocarcinoma with complete response to androgen blockade
MDedge Hematology and Oncology
Extramedullary plasmacytoma of the thyroid, refractory to radiation therapy and treated with bortezomib
MDedge Hematology and Oncology
Immunotherapy-related adverse effects: how to identify and treat them in the emergency department
MDedge Hematology and Oncology
ESMO scale offers guidance on cancer targets
MDedge Hematology and Oncology
ASCO updates guidance on prophylaxis for adults with cancer-related immunosuppression
MDedge Hematology and Oncology
AACR: New cancer cases predicted to rise above 2.3 million by 2035
MDedge Hematology and Oncology
Skin signs may be good omens during cancer therapy
MDedge Hematology and Oncology
Osteonecrosis of jaw in mRCC higher with denosumab/antiangiogenics
MDedge Hematology and Oncology
Bacteremic sepsis in ALL linked to later cognitive issues
MDedge Hematology and Oncology